RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos, Chao Zhang, Gideon E. Bollag et al. · Nature · 2010
Cited by 1,811 works. doi:10.1038/nature08902 Open-access PDF
Authors
References
- Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
- BRAF mutation predicts sensitivity to MEK inhibition
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- The RAF proteins take centre stage
- Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
- Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling
- V599EB-RAF is an Oncogene in Melanocytes
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- Paradoxical activation of Raf by a novel Raf inhibitor